Q32 Bio (QTTB) Stock Price

Q32 Bio Price

NASDAQ·CLOSED
8.71
​
Market closed

Revenue at Q32 Bio has contracted by 26.3% per year over the past 5 years to 1.16 M USD. For Q32 Bio, the net margin of -9,771.7% is down versus -6,222.8% a few years ago. The consensus 12-month price target for Q32 Bio is 10.20 USD, about 17.1% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.

Q32 Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q32 Bio business model & stock analysis

Homology Medicines, Inc. generates revenue by developing and commercializing treatments for rare diseases at the genetic level. The company operates as a technology platform focused on creating a pipeline of new medicines that address and cure the underlying cause of monogenic diseases. Its lead product candidate, HMI-102, is a gene therapy designed for the treatment of phenylketonuria (PKU), with the PKU program specifically targeting adults using this gene therapy approach. The firm utilizes its suite of 15 adeno-associated virus vectors (AAVHSCs) to enable a method of gene editing called gene correction, allowing for precise targeting of disease-relevant tissues across both gene editing and gene therapy modalities.

Frequently asked questions about Q32 Bio

Analysts currently set an average price target of 11.56 USD for the Q32 Bio stock (median: 10.20 USD), implying +32.0 % versus the latest price. The consensus is based on 8 analyst ratings.

14 analysts currently rate the Q32 Bio stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Q32 Bio to generate revenue of 1.25 M USD and earnings per share of -2.30 USD.

Converted at the current exchange rate, the Q32 Bio share trades at 7.78 EUR (8.71 USD).

The Q32 Bio share (QTTB) is listed on 5 stock exchanges, including: NASDAQ (FIXX), London (0T6G.L), Frankfurt (35H.F), München (35H.MU).

The expected revenue of Q32 Bio is 1.25 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Q32 Bio is -21.40 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Q32 Bio is currently -3.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Q32 Bio stock.

The price-to-sales ratio (P/S) of Q32 Bio is currently 64.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Q32 Bio stock.

The Eulerpool Quality Score for Q32 Bio is 3/10.

The ISIN of Q32 Bio is US7469641051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Q32 Bio is A2JGTY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Q32 Bio is QTTB. The ticker symbol is used to trade Q32 Bio shares on the stock exchange.

Fair ValueTerminal
7.75 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 28, 2018
ISIN
US7469641051
Cusip
438083107
Sedol
BFMMJ23
Market capitalization
107.13 M USDMicro Cap
52-Week Range
PEG
0.07
P/E ratio
P/Ee 2025
-2.35
P/Ee 2026
-3.79
P/Ee 2027
-3.35
P/Ee 2028
-3.33
P/Ee 2029
-4.40
P/Se
40.59
EV/EBIT
—
P/B Ratio
18.86
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-255.53 %
Last updated Nov 4, 2026, 6:21 PM

Q32 Bio Peer Group

Q32 Bio Ticker

FRANKFURT · 35H.FLONDON · 0T6G.LLONDON STOCK EXCHANGE · 0T6G.LMUNICH · 35H.MUNASDAQ · FIXX

All fundamentals and in-depth analysis of Q32 Bio

Our stock analysis for Q32 Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Q32 Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.